CERUS CORP (CERS) - Q2 2026 Filing Summary
Business Context and Reporting Period
This summary covers the Quarterly Report on Form 10-Q for Cerus Corporation for the period ended June 30, 2026. Cerus is a medical technology company focused on the development and commercialization of the INTERCEPT Blood System for pathogen reduction in platelets, plasma, and red blood cells. The company operates globally, with significant commercial activities in the U.S. and Europe, and relies on government contracts (BARDA, DoD) for the development of its red blood cell system.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Total Revenue | $63.3 million | $60.1 million | $123.2 million | $109.0 million |
| Product Revenue | $57.4 million | $52.4 million | $111.1 million | $95.7 million |
| Government Contract Revenue | $5.9 million | $7.7 million | $12.1 million | $13.3 million |
| Gross Profit (Product) | $29.5 million | $29.0 million | $57.4 million | $54.4 million |
| Product Gross Margin | 51.4% | 55.2% | 51.7% | 56.9% |
| Net Loss (Attributable to Cerus) | $(2.9) million | $(5.7) million | $(4.6) million | $(13.4) million |
| Net Loss Per Share (Diluted) | $(0.01) | $(0.03) | $(0.02) | $(0.07) |
| Cash & Short-Term Investments | $56.3 million (as of June 30, 2026) | |||
| Total Debt | $64.9 million (as of June 30, 2026) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 5% in Q2 and 13% YTD compared to the prior year periods. Product revenue growth was driven by increased sales volume of disposable platelet and plasma kits and INTERCEPT Fibrinogen Complex (IFC) to U.S. customers.
- Government Contract Decline: Government contract revenue decreased 24% in Q2 and 9% YTD. This was primarily due to the completion of the FDA agreement in September 2025 and decreased activity levels under BARDA agreements relative to the prior year.
- Margin Compression: Product gross margins declined from 55% to 51% in Q2 and from 57% to 52% YTD. Management attributed this to foreign exchange rates, inventory costs, and the impact of import tariffs.
- Expense Management: Research and Development (R&D) expenses decreased 24% in Q2 and 19% YTD, driven by reduced costs related to government contract work and the LED-based illuminator. Selling, General, and Administrative (SG&A) expenses increased slightly (8% in Q2, 3% YTD).
- Debt Refinancing: On June 5, 2026, the company entered into a Second Amended and Restated Credit Agreement, refinancing its term loan to $35.0 million and increasing its revolving credit facility to $30.0 million. Total debt decreased from $83.9 million at year-end 2025 to $64.9 million at June 30, 2026.
Guidance, Outlook, and Risks
- Red Blood Cell System Development: The company continues to develop the red blood cell system. Enrollment for the RedeS clinical trial was completed in 2025, with completion anticipated in the second half of 2026. The company expects to need additional clinical trial data to supplement the ReCePI and RedeS trials before a PMA submission to the FDA. A new MDR application for the EU was submitted in July 2025 after a previous application was closed due to insufficient data on impurity profiles.
- Government Funding: The company relies heavily on BARDA funding. In July 2026, BARDA extended the 2016 agreement to March 2027 and the 2024 agreement to September 2031, increasing the total funding opportunity under the 2024 agreement to $209.0 million. However, funding is contingent on meeting milestones and government budget availability.
- Supply Chain and Tariffs: The company faces risks from global supply chain disruptions, inflation, and tariffs. It relies on Fresenius as the sole supplier for finished disposable kits. Tariffs and trade tensions have increased costs and negatively impacted gross margins.
- Liquidity: Management believes current cash, cash equivalents, and short-term investments, along with expected government contract reimbursements, are sufficient to meet capital requirements for at least the next 12 months.
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $56.3 million in liquid assets against the ongoing burn rate and the timing of expected BARDA reimbursements.
- Red Blood Cell Trial Status: Monitor the completion of the RedeS trial and the FDA's response to the data, as this is critical for future revenue potential from the red blood cell system.
- Margin Trends: Track the impact of tariffs and foreign exchange on gross margins, as these factors have recently compressed profitability.
- Debt Covenants: Review the financial covenants in the new Term Loan and Revolving Loan agreements to ensure compliance and assess refinancing risks.
- Customer Concentration: Note that the American Red Cross accounted for 33% of product revenue in the six months ended June 30, 2026, highlighting significant customer concentration risk.